Klin Farmakol Farm. 2017;31(2):23-26 | DOI: 10.36290/far.2017.014
Apixaban has been available for the treatment of venous thromboembolic disease for more than two years
- II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha
- Ústav farmakologie, 3. LF UK Praha
Apixaban – a direct, oral, selective activated factor Xa inhibitor – has been approved since the year 2014 for the treatment ofacute venous thrombosis and the so-called low-risk pulmonary embolism (in addition to the registration for the prevention ofsystemic embolization in non-valvular atrial fibrillation and the prevention of venous thromboembolism in orthopaedics). It isan effective and very safe option for oral monotherapy since the establishment of the diagnosis of thromboembolic disease inboth outpatient and inpatient settings.
Keywords: thromboembolic disease (TED), apixaban, acute venous thrombosis, acute low-risk pulmonary embolism, secondary
prevention of TED.
Published: July 1, 2017 Show citation
References
- Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009; 37(1): 74-81.
Go to original source... 
Go to PubMed... - Agnelli G, Buller HR, Cohen A, and AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9): 799-808. Go to original source...
- Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368(8): 699-708. Go to original source...
- The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510. Go to original source...
- Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S for the EINSTEIN investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med 2010; 363(26): 2499-2510. Go to original source...
- Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of venous Thrombembolism. New Engl J Med 2017; 376(13): 1211-1222. Go to original source...
- Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959. Go to original source...
- Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 36. Go to original source...
- Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Circulation. 2014; 129(7): 764-772. Go to original source...
- Schulman S, Kakkar AK, Goldhaber SZ, et al. RE-COVER II Trial Investigators.Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. N Engl J Med. 2009 Dec 10; 361(24): 2342-2352. Go to original source...
- Schulman S, RE-MEDY, RE-SONATE Trial Investigators. Extended anticoagulation in venous thromboembolism. N Engl J Med. 2013; 368(24): 2329. Go to original source...
- Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15): 1406-1415. Go to original source...
- Pernod G, Sanchez O, Coiuturaud F, et al. The PADIS_PE Randomization Clinical Trial. JAMA 2015; 314(1): 31-40. Go to original source...
- Andreozzi GM, Bignamini AA, Davi G, et al. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The SURVET Study: A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial. Circulation. 2015; 132(20): 1891-1897. Go to original source... Go to PubMed...